# 1. Financial Performance ## A. Key Figures * **Revenue from Operations:** **₹190 Cr** Q2 FY'26 (+66% YoY, +9% QoQ) · **₹114 Cr** Q2 FY'25 * **PAT:** **₹59 Cr** Q2 FY'26 (+121% YoY, +15% QoQ) * **EBITDA:** **₹92 Cr** Q2 FY'26 (+129% YoY, +17% QoQ) · **48% margin** * **Gross Margin:** **85%** Q2 FY'26 (vs. 91% prior year) ## B. Revenue Growth * **Robust Top-Line Acceleration:** Revenue growth significantly outpaced prior periods, driven by **78% YoY product segment expansion** and balanced contribution from services, which now represent half of total revenue. * **Pricing and Utilization Strength:** Average revenue per bed increased sequentially, reflecting **positive pricing dynamics and operational leverage** across facilities. ## C. Profit Margins * **Exceptional Bottom-Line Expansion:** PAT and EBITDA surged well above revenue growth, underscoring **strong operating leverage and cost discipline** despite gross margin headwinds. * **Gross Margin Pressure Explained:** Decline in gross margin attributed to **reclassification of consumables to direct costs** and **5% higher consumable expenses**, not underlying operational deterioration. * **Sustained Profitability Trajectory:** Despite above-the-line cost shifts, net profit margins improved to **31%**, reflecting efficient SG&A management and scalability. ## D. Balance Sheet * **Enhanced Financial Reporting Rigor:** Transition to Ind-AS and main board standards, supported by GT-led revisions, resulted in **more conservative lease accounting (10-year agreements)** and improved transparency. * **Strong Cash Position & Strategic Focus:** Elevated cash balances at year-end were strategic, ensuring continuity; management is prioritizing **private sector partnerships and health insurance monetization**. --- # 2. Bed Capacity & Utilization ## A. Key Figures * **Total Bed Capacity:** **2,802 beds** (target: 2,800) · **582 beds added** in period * Operational Beds: 2,802 beds operational · 57% occupancy rate (target: 70–80%) * **Hospital Count:** **58 hospitals** (net +3) · **61 clinics** (unchanged) ## B. Hospital Expansion * **Accelerated Infrastructure Growth:** Bed capacity expansion significantly ahead of schedule, surpassing annual target with aggressive additions across existing and new facilities. * **Strategic Acquisitions & Geographic Diversification:** Two new college takeovers underway—Saraswati Group (Vrindavan) and Buldhana—with expansion into **Guwahati (operational)**, Calcutta (site finalized), and multiple southern cities under evaluation. * **Long-Term Scale Vision:** Management reaffirmed ambition to reach **7,000–10,000 beds in 3–5 years**, representing only **5% of India’s private allopathic capacity**, signaling vast white-space potential. * **Near-Term Focus on Utilization:** Plans to add **200–300 beds in next six months**, with strategic emphasis on improving occupancy before further scaling. ## C. Bed Occupancy * **Occupancy Stability with Embedded Upside:** System-wide occupancy holds at **57%**, but exceeds **80% on a consistent base of 1,600 beds**, highlighting strong demand in mature facilities and underutilization in newly added capacity. * **High-Performance Acquired Assets:** The **Mohali medical college (100 beds)** achieves **90% occupancy**, demonstrating successful integration and demand for specialized offerings. * **Government Contribution Minimized:** Public sector reliance reduced to **4%**, enabling focus on higher-margin private patient growth and urban market penetration. ## D. International Operations * **Profitable International Footprint:** Operations in **Nepal and Dubai/Abu Dhabi** are live, with **one center 100% operational and profitable**; holding company recently established for Gulf expansion. * **New Market Entry in Central Asia:** Expansion into **Kazakhstan** via a health center staffed by **one doctor and therapist**, marking low-cost, scalable entry into new geographies. --- # 3. Product & OTC Launches ## A. Key Figures * OTC Sales: ₹2.25 Cr online in one month · ₹2.5 Cr last month on quick commerce (Zepto, Blinkit) * **Injectable Device Sales:** **₹1–5 Cr** monthly * **OTC Revenue Potential:** **₹300–500 Cr** estimated * **Franchise Network:** **35** franchisees · **46** NAVH centers (+5 in pipeline) ## B. New Product Pipeline * **Accelerated Launch Plan:** Company to introduce **15 to 20 new products** in next 6–12 months, up from prior guidance, with **10 expected by FY'26 end**. * **Scientific Differentiation:** Ayurvedic medicines for BP, diabetes, kidney, liver, and depression backed by **clinical trials**, providing first-mover advantage in scientifically validated Ayurveda. * **Exclusive Distribution Breakthrough:** Finalizing partnership with **Entero**, a listed B2B platform with **1 lakh pharmacies**, under an **exclusive Ayurveda agreement** to drive nationwide scale. ## C. OTC Sales Trends * **Strong Early Traction:** OTC business shows **positive momentum** with repeat orders and rapid adoption, boosted by **festival-driven demand**. * **Multi-Channel Expansion:** Products now available via company website, OTC channels, and **quick commerce platforms** (Zepto, Blinkit), enabling broad consumer access. ## D. Franchise Rollout * **Aggressive Expansion:** Plans to launch **50 new Jeena Sikho hospitals** in franchise model within a month, requiring **no capital investment** from the company. * **Strategic Market Penetration:** Targeting underpenetrated **East and South India** through franchise-led rollout with **revenue-sharing model**, leveraging partner-funded growth. --- # 4. Diagnostic & Lab Integration ## A. Key Figures * **Chandan Investment:** **₹10 Cr** invested (pending **₹30 Cr** post-warrant) * Per-Center Diagnostic Capex: ₹50 Lakh–₹1.5 Cr (Chandan-funded) * **Lab Machinery Add-on:** **₹5 Cr** additional equipment installed at Chandan’s cost * **Diagnostic Commission Margins:** **50–60%** industry standard ## B. Chandan Partnership * **Strategic Full-Coverage Tie-Up:** 100% of current and future hospitals included, with Chandan fully funding diagnostic infrastructure and staffing across 19 Delhi NCR centers. * **Patient-Centric Revenue Share:** Lab commissions are converted into **up to 30% medicine discounts**—not cashback—to boost conversion, retention, and testing authenticity. * **Data & Control Strategy:** A one-time investment secures data access and collaboration rights; while 51% ownership is preferred for control, a minimal stake was taken to avoid fragmented minority positions. * **No Upfront Payment:** No funds disbursed to Chandan yet, pending warrant approval, aligning with structured financial discipline. ## C. In-House Testing * **Integrated Diagnostic Rollout:** 34 Chandan centers operational within facilities as of November 1, offering free basic tests (CBC, lipid, thyroid, etc.) to drive patient acquisition. * **Advanced Testing Onshored:** High-cost cancer marker tests, previously outsourced at **₹75,000/patient**, are being brought in-house via capital-intensive machinery to improve access and economics. * **Full-Service Lab Expansion:** Chandan is deploying comprehensive diagnostics including ultrasound, fibro care, and radio diagnostics, enhancing clinical depth. ## D. Insurance Enablement * **NABL Certification Unlocks Insurance Growth:** Chandan’s NABL-accredited labs enable valid, claim-compliant diagnostics, streamlining health insurance processing and expanding monetization potential. --- # 5. Customer Acquisition & Retention ## A. Key Figures * **Patient Growth:** **8,616 IPD** (Q1) · **9,614 IPD** (Q2) · **124,364 OPD** (Q1) · **140,144 OPD** (Q2) * **Segment Growth:** **66% YoY** growth in product & services segments * **Market Opportunity:** Targeting **10 crore potential customers** in BP medication segment * **Cardholder Base:** **40 lakh** existing Chandan Privilege cardholders to access Manish Grover centers * **Insurance Growth:** **20% QoQ increase** in private insurance business ## B. Cashback Program * **Strategic Incentive Model:** Launching a **30% patient cashback** via card system, funded by a **50% commission on global sales**, driving repeat visits and trust. * **Integrated Referral Ecosystem:** New **referral card** to reward points across consultations, tests, admissions, and medicine purchases, enhancing retention. * **Technology Enablement:** **Salesforce integration** has enabled advanced data segregation and reporting, making the card and referral system operationally feasible. * **Regional Engagement Push:** Expanding customer support to **7 regional languages** and launching **AI-dubbed educational videos** to improve outreach and accessibility. ## C. Patient Footfall * **Strong Volume Momentum:** Robust **quarterly increase in both IPD and OPD footfall**, supported by expanded delivery chain and digital segment strength. * **Scalable Geographic Reach:** Operations span **23 states and 100+ cities**, with strong traction in new hospitals and no intent to de-prioritize service revenue. * **Market Share Ambition:** Targeting high-demand segments like BP care, leveraging **free testing campaigns** and rapid promotional rollouts to accelerate patient acquisition. * **Preventive Care Advocacy:** Leadership promoting **biannual panchkarma detoxification** as essential preventive care, positioning clinics as wellness destinations. ## D. Regional Outreach * **Digital Health Education:** Manish Grover leveraging **YouTube and social media** to drive preventive healthcare awareness and build national brand equity. --- # 6. Risks & Regulatory Delays ## A. Government Payment Delays * **Reduced Government Exposure:** Government business scaled back to **3%** of total operations amid payment delays and structural constraints. * **Pending Resolution:** Expansion on hold pending resolution of **payment turnaround time**; new government portal expected to reduce TAT to **2.5 months**. * **Operational Pause:** Full resumption of government-linked services awaits confirmation of timely payments and final settlement of pending dues. * **Structural Hurdles:** Fixed reimbursement rate of **₹8,000/day** and mandatory **25% advance income tax** cited as key financial impediments. ## B. NOC Approvals * **Partial Bed Utilization:** **2,220 beds** operational despite delays from pending fire and pollution NOCs at select locations. * **Regulatory Bottlenecks:** New college tie-ups slowed by protracted government NOC processes, particularly for fire and pollution clearances. * **Project Progress:** Aurangabad college construction to commence post-havan ceremony; all critical operational approvals (NABH, pollution, fire, Hiding) now secured. ## C. College Tie-Up Delays * **Continued Strategic Focus:** Despite slowdown, hospital–college tie-ups remain a priority, with **three active partnerships** in place since Q1 FY. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Guidance FY'26:** **₹650 Cr** (vs. FY'25: ₹469 Cr) * **Profit Guidance FY'26:** **₹125–130 Cr** (vs. FY'25: ₹91 Cr) * **Target Profit Margin:** **20% to 25%** for next 1–3 years ## B. Revenue & Profit Outlook * **On-Track Performance:** Company is on track or slightly ahead of FY'26 revenue and profit targets, supported by finalized October results and stable early November trends. * **Near-Term Headwinds:** Q3 seasonality (November–December) expected to dampen growth due to reduced patient inflows in cold weather, limiting upside beyond current guidance. * **Future Growth Levers:** OTC, online marketing, and product sales projected to contribute **₹300–500 Cr** in revenue over the next 1–2 years, though FY'27 guidance remains unquantified due to new business model integration. * **Execution Pressure:** Accelerated delivery timelines—from six to three months—are increasing operational execution intensity. ## C. Expansion & Strategic Focus * **Expansion Paused for Stability:** Growth beyond existing three colleges is on hold until operational excellence is achieved; focus remains on optimizing current assets. * **Catalyst-Driven Hospital Rollout:** Anticipated inclusion of Ayurveda in Ayushman Yojana could trigger aggressive expansion into **5–10 hospitals across India**. * **Premiumization Strategy:** New VIP center to launch in historic fort within 2–4 months; 50 received resort proposals under review for conversion into high-end healthcare facilities. * **Franchise & Market Model Shift:** Transitioned from revenue-sharing to rent-based model; paused 10–15 potential tie-ups to prioritize operational efficiency. * **Global Ambition, India-First Execution:** US expansion on hold per investor advice; long-term vision targets becoming **India’s, then Asia’s, then global No. 1** naturopathy/Ayurveda provider over 5–10 years. * **Profitability Caution:** Luxury resort ventures currently loss-making; management urges tempered expectations on franchise growth amid sustainability concerns.